Page 176 - Read Online

Cheng et al. Advances in liver fibrosis

Hepatology 2014;60:1911-9. G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G,
102. Chong CC, Wong GL, Chan AW, Wong VW, Fong AK, Cheung Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-
YS, Wong J, Lee KF, Chan SL, Lai PB, Chan HL. Liver stiffness acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev
measurement predicts high-grade post-hepatectomy liver failure: a 2017;6:CD012143.
prospective cohort study. J Gastroenterol Hepatol 2017;32:506-14. 117. Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren
103. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression
J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical of fibrosis and portal hypertension in HCV-associated cirrhosis and
outcomes after successful HCV therapy: a 5-year follow-up of 150 sustained virologic response after interferon-free antiviral therapy. J
patients. Hepatology 2009;49:729-38. Viral Hepat 2016;23:994-1002.
104. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, 118. Bachofner JA, Valli PV, Kroger A, Bergamin I, Kunzler P, Baserga
Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L,
JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Mullhaupt B, Terziroli Beretta-Piccoli B, Mertens JC. Direct antiviral
Regression of cirrhosis during treatment with tenofovir disoproxil agent treatment of chronic hepatitis C results in rapid regression
fumarate for chronic hepatitis B: a 5-year open-label follow-up study. of transient elastography and fibrosis markers fibrosis-4 score and
Lancet 2013;381:468-75. aspartate aminotransferase-platelet ratio index. Liver Int 2017;37:369-
105. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, 76.
Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje 119. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-
U, Beebe S, Kreter B. Long-term entecavir therapy results in the Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago
reversal of fibrosis/cirrhosis and continued histological improvement M, Romero-Gomez M. Weight loss through lifestyle modification
in patients with chronic hepatitis B. Hepatology 2010;52:886-93. significantly reduces features of nonalcoholic steatohepatitis.
106. Buti M, Gane E, Aguilar Schall R, Tsai NC, Washington MK, Lee Gastroenterology 2015;149:367-78.e5; quiz e14-5.
SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn 120. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK,
P, Subramanian GM, Marcellin P. Hepatic steatosis does not Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan
predict regression of liver cirrhosis in chronic hepatitis b (CHB) HL. Community-based lifestyle modification programme for non-
patients treated with tenofovir disoproxil fumarate (TDF). J Hepatol alcoholic fatty liver disease: a randomized controlled trial. J Hepatol
2015;60:S294-5. 2013;59:536-42.
107. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan 121. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis:
HY, Chan FK, Sung JJ, Chan HL. Metabolic syndrome increases the pioglitazone improves liver histology and fibrosis in patients with
risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111-7. non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012;35:66-
108. Yoon H, Lee JG, Yoo JH, Son MS, Kim DY, Hwang SG, Rim KS. 75.
Effects of metabolic syndrome on fibrosis in chronic viral hepatitis. 122. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role
Gut Liver 2013;7:469-74. of thiazolidinediones in non-alcoholic steatohepatitis - a systematic
109. Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan review and meta analysis. J Hepatol 2011;55:1383-90.
HY, Tse CH, Wong VW. Coincidental metabolic syndrome increases 123. Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative
the risk of liver fibrosis progression in patients with chronic hepatitis effectiveness of pharmacological interventions for nonalcoholic
B--a prospective cohort study with paired transient elastography steatohepatitis: a systematic review and network meta-analysis.
examinations. Aliment Pharmacol Ther 2014;39:883-93. Hepatology 2015;62:1417-32.
110. Cheng JY, Wong VW, Tse YK, Chim AM, Chan HL, Wong GL. 124. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van
Metabolic syndrome increases cardiovascular events but not hepatic Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM,
events and death in patients with chronic hepatitis B. Hepatology Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM,
2016;64:1507-17. Tonascia J, Brunt EM, Kleiner DE, Doo E, Network NCR. Farnesoid
111. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-
fibrosis progression is uncommon in patients with inactive chronic alcoholic steatohepatitis (FLINT): a multicentre, randomised,
hepatitis B: a prospective cohort study with paired transient placebo-controlled trial. Lancet 2015;385:956-65.
elastography examination. J Gastroenterol Hepatol 2013;28:1842-8. 125. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ,
112. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida
fibrosis progression in chronic hepatitis B patients positive for A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis
hepatitis B e antigen: a prospective cohort study with paired transient Clinical Research N. Design and validation of a histological scoring
elastography examination. J Gastroenterol Hepatol 2013;28:1762-9. system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-
113. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka 21.
O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida 126. Moon HJ, Finney J, Ronnebaum T, Mure M. Human lysyl oxidase-
H, Omata M. Histologic improvement of fibrosis in patients with like 2. Bioorg Chem 2014;57:231-41.
hepatitis C who have sustained response to interferon therapy. Ann 127. Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC.
Intern Med 2000;132:517-24. Pathogenesis and novel treatment options for non-alcoholic
114. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros steatohepatitis. Lancet Gastroenterol Hepatol 2016;1:56-67.
PJ, Marcellin P, Balart L, Alberti A, Craxi A. Effect of peginterferon 128. Gilead Terminates Phase 2 Study of Simtuzumab in Patients With
alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of Idiopathic Pulmonary Fibrosis. Available from: http://www.gilead.
individual patient data. Hepatology 2004;39:333-42. com/news/press-releases/2016/1/gilead-terminates-phase-2-study-
115. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis. [Last
Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b accessed on 26 July 2017].
and ribavirin on liver fibrosis in patients with chronic hepatitis C. 129. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwel SHea. GS-
Gastroenterology 2002;122:1303-13. 4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone
116. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser or in combination with simtuzumab for the treatment of non-alcoholic
168 Hepatoma Research ¦ Volume 3 ¦ August 08, 2017